HUTCHMED (HCM) Projected to Announce Quarterly Earnings on Thursday

HUTCHMED (NASDAQ:HCM) is projected to post its H1 2026 results before the market opens on Thursday, July 30th. Analysts expect HUTCHMED to announce earnings of $0.15 per share and revenue of $306.40 million for the quarter. Parties are encouraged to explore the company’s upcoming H1 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

HUTCHMED Trading Down 0.5%

NASDAQ:HCM opened at $11.12 on Thursday. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. HUTCHMED has a 1 year low of $9.77 and a 1 year high of $19.50. The stock’s 50 day simple moving average is $11.15 and its two-hundred day simple moving average is $13.36.

Institutional Trading of HUTCHMED

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. boosted its position in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after buying an additional 698 shares during the period. Bank of America Corp DE grew its stake in shares of HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after buying an additional 3,035 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of HUTCHMED by 34.2% in the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after buying an additional 5,538 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of HUTCHMED by 19.7% in the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after buying an additional 4,116 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in shares of HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock worth $1,413,000 after acquiring an additional 7,342 shares during the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Morgan Stanley set a $13.60 target price on HUTCHMED in a report on Thursday, May 28th. Weiss Ratings upgraded HUTCHMED from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, July 17th. Finally, Bank of America lowered their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $15.30.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.